Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial

被引:105
|
作者
Liu, You-Ping [1 ,2 ]
Wen, Yi-Hui [1 ]
Tang, Jun [4 ]
Wei, Yi [1 ]
You, Rui [2 ]
Zhu, Xiao-Lin [1 ]
Li, Jian [1 ]
Chen, Lin [1 ]
Ling, Li [6 ,7 ]
Zhang, Ning [5 ]
Zou, Xiong [2 ]
Hua, Yi-Jun [2 ]
Chen, You-Mou [4 ]
Chen, Lei [3 ]
Lu, Li-Xia [3 ]
Chen, Ming-Yuan [2 ]
Wen, Wei-Ping [1 ,8 ]
机构
[1] Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Guangzhou Key Lab Otorhinolaryngol,Dept Otolaryng, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China,Canc Ctr, Collaborat Innovat Ctr Canc Med,Dept Nasopharynge, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China,Canc Ctr, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China
[4] First Peoples Hosp Foshan, Dept Otolaryngol, Foshan, Peoples R China
[5] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China
[6] Sun Yat Sen Univ, Dept Med Stat, Sch Publ Hlth, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Ctr Migrant Hlth Policy, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Otolaryngol, Guangzhou, Peoples R China
来源
LANCET ONCOLOGY | 2021年 / 22卷 / 03期
基金
中国国家自然科学基金;
关键词
3-DIMENSIONAL CONFORMAL RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; CHEMOTHERAPY; REIRRADIATION; CANCER; EVENTS;
D O I
10.1016/S1470-2045(20)30673-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The role of surgery compared with reirradiation in the primary treatment of patients with resectable, locally recurrent nasopharyngeal carcinoma (NPC) who have previously received radiotherapy is a matter of debate. In this trial, we compared the efficacy and safety outcomes of salvage endoscopic surgery versus intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent NPC. Methods This multicentre, open-label, randomised, controlled, phase 3 trial was done in three hospitals in southern China. We included patients aged 18-70 years with a Karnofsky Performance Status score of at least 70 who were histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus. Eligible patients were randomly assigned (1:1) to receive either endoscopic nasopharyngectomy (ENPG group) or IMRT (IMRT group). Randomisation was done manually using a computer-generated random number code and patients were stratified by treatment centre. Treatment group assignment was not masked. The primary endpoint was overall survival, compared between the groups at 3 years. Efficacy analyses were done by intention to treat. Safety analysis was done in patients who received treatment according to the treatment they actually received. This trial was prospectively registered at the Chinese Clinical Trial Registry, ChiCTRTRC-11001573, and is currently in follow-up. Findings Between Sept 30, 2011, and Jan 16, 2017, 200 eligible patients were randomly assigned to receive either ENPG (n=100) or IMRT (n=100). At a median follow-up of 56.0 months (IQR 42.0-69.0), 74 patients had died (29 [29%] of 100 patients in the ENPG group and 45 [45%] of 100 patients in the IMRT group). The 3-year overall survival was 85.8% (95% CI 78.9-92.7) in the ENPG group and 68.0% (58.6-77.4) in the IMRT group (hazard ratio 0.47, 95% CI 0.29-0.76; p=0.0015). The most common grade 3 or worse radiation-related late adverse event was pharyngeal mucositis (in five [5%] of 99 patients who underwent ENPG and 26 [26%] of 101 patients who underwent IMRT). Five [5%] of the 99 patients who underwent ENPG and 20 [20%] of the 101 patients who underwent IMRT died due to late toxic effects specific to radiotherapy; attribution to previous radiotherapy or trial radiotherapy is unclear due to the long-term nature of radiation-related toxicity. Interpretation Endoscopic surgery significantly improved overall survival compared with IMRT in patients with resectable locally recurrent NPC. These results suggest that ENPG could be considered as the standard treatment option for this patient population, although long-term follow-up is needed to further determine the efficacy and toxicity of this strategy. (C) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [41] Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial
    Mao, Yan-Ping
    Wang, Shun-Xin
    Gao, Tian-Sheng
    Zhang, Ning
    Liang, Xiao-Yu
    Xie, Fang-Yun
    Zhang, Yuan
    Zhou, Guan-Qun
    Guo, Rui
    Luo, Wei-Jie
    Li, Yong-Jie
    Liang, Shao-Qiang
    Lin, Li
    Li, Wen-Fei
    Liu, Xu
    Xu, Cheng
    Chen, Yu -Pei
    Lv, Jia-Wei
    Huang, Shao-Hui
    Liu, Li-Zhi
    Li, Ji-Bin
    Chen, Lei
    Sun, Ying
    Ma, Jun
    Tang, Ling-Long
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 380
  • [42] Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
    Pignata, Sandro
    Scambia, Giovanni
    Schettino, Clorinda
    Arenare, Laura
    Pisano, Carmela
    Lombardi, Davide
    De Giorgi, Ugo
    Andreetta, Claudia
    Cinieri, Saverio
    De Angelis, Carmine
    Priolo, Domenico
    Casanova, Claudia
    Rosati, Marta
    Greco, Filippo
    Zafarana, Elena
    Schiavetto, Ilaria
    Mammoliti, Serafina
    Cecere, Sabrina Chiara
    Salutari, Vanda
    Scalone, Simona
    Farolfi, Alberto
    Di Napoli, Marilena
    Lorusso, Domenica
    Gargiulo, Piera
    Califano, Daniela
    Russo, Daniela
    Spina, Anna
    De Cecio, Rossella
    Chiodini, Paolo
    Perrone, Francesco
    LANCET ONCOLOGY, 2023, 24 (03): : 286 - 296
  • [43] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
    Powles, Thomas
    Duran, Ignacio
    van der Heijden, Michiel S.
    Loriot, Yohann
    Vogelzang, Nicholas J.
    De Giorgi, Ugo
    Oudard, Stephane
    Retz, Margitta M.
    Castellano, Daniel
    Bamias, Aristotelis
    Flechon, Aude
    Gravis, Gwenaelle
    Hussain, Syed
    Takano, Toshimi
    Leng, Ning
    Kadel, Edward E., III
    Banchereau, Romain
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Cui, Na
    Shen, Xiaodong
    Derleth, Christina L.
    Green, Marjorie C.
    Ravaud, Alain
    LANCET, 2018, 391 (10122): : 748 - 757
  • [44] Dysphagia- optimised intensity-modulated radiotherapy versus standard intensity- modulated radiotherapy in patients with head and neck cancer ( DARS): a phase 3, multicentre, randomised, controlled trial (vol 24, pg 868, 2023)
    Nutting, C.
    Finneran, L.
    Roe, J.
    LANCET ONCOLOGY, 2023, 24 (08): : E328 - E328
  • [45] Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial (vol 6, pg 292, 2021)
    Adamson, D.
    Byrne, A.
    Porter, C.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (04): : E3 - E3
  • [46] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
    Brand, Douglas H.
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Loblaw, Andrew
    Chu, William
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Henderson, Daniel
    Brown, Stephanie
    Cruickshank, Clare
    Burnett, Stephanie
    Duffton, Aileen
    Griffin, Clare
    Hinder, Victoria
    Morrison, Kirsty
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    LANCET ONCOLOGY, 2019, 20 (11): : 1531 - 1543
  • [47] Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial
    Piperno-Neumann, Sophie
    Le Deley, Marie-Cecile
    Redini, Francoise
    Pacquement, Helene
    Marec-Berard, Perrine
    Petit, Philippe
    Brisse, Herve
    Lervat, Cyril
    Gentet, Jean-Claude
    Entz-Werle, Natacha
    Italiano, Antoine
    Corradini, Nadege
    Bompas, Emmanuelle
    Penel, Nicolas
    Tabone, Marie-Dominique
    Gomez-Brouchet, Anne
    Guinebretiere, Jean-Marc
    Mascard, Eric
    Gouin, Francois
    Chevance, Aurelie
    Bonnet, Naima
    Blay, Jean-Yves
    Brugieres, Laurence
    LANCET ONCOLOGY, 2016, 17 (08): : 1070 - 1080
  • [48] Long-term Outcomes and Prognostic Factors of Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma using Intensity-modulated Radiotherapy
    Han, Fei
    Zhao, Chong
    Huang, Shao-Min
    Lu, Li-Xia
    Huang, Ying
    Deng, Xiao-Wu
    Mai, Wei-Yuan
    Teh, Bin S.
    Butler, E. Brian
    Lu, Tai-Xiang
    CLINICAL ONCOLOGY, 2012, 24 (08) : 569 - 576
  • [49] Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Chu, William
    Loblaw, Andrew
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Armstrong, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Duffton, Aileen
    Brand, Douglas H.
    Henderson, Daniel
    Morrison, Kirsty
    Brown, Stephanie
    Pugh, Julia
    Burnett, Stephanie
    Mahmud, Muneeb
    Hinder, Victoria
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    LANCET ONCOLOGY, 2022, 23 (10): : 1308 - 1320
  • [50] Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial
    Afferi, Luca
    Moschini, Marco
    Mattei, Agostino
    Montorsi, Francesco
    Briganti, Alberto
    Cathelineau, Xavier
    Sanchez-Salas, Rafael
    EUROPEAN UROLOGY, 2020, 78 (02) : 289 - 290